Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 6/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615430 | 0.87 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL14528969 | 0.85 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL22288716 | 0.84 | KDM4E (0.52) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL13702336 | 0.82 | TAS1R3 (0.56) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL4588114 | 0.80 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL25216423 | 0.80 | TAS1R3 (0.56) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL13753115 | 0.79 | ALDH1A1 (0.59) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL3976727 | 0.77 | TAS1R3 (0.53) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL612663 | 0.77 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL13407792 | 0.76 | TAS1R3 (0.59) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872381-B1 | Radiopharmaceuticals for diagnosing Alzheimer's disease | SCHERING AG (DE) | 2005-03-29 | — | — | US | claimed |
| US-6676926-B2 | FOR ADMINISTERING TO A HUMAN IN NEED OF SUCH DIAGNOSIS AND MEASURING THE RADIOACTIVITY ARISING FROM THE ADMINISTRATION OF THE COMPOUND TO THE HUMAN EITHER BY USING A GAMMA CAMERA OR BY POSITRON EMISSION TOMOGRAPHY | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | claimed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| EP-1660089-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MYOCARDITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1332138-B1 | RADIOPHARMACEUTICALS FOR DIAGNOSING ALZHEIMER'S DISEASE | SCHERING AG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-6977258-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-20 | — | — | US | disclosed |
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-20020131932-A1 | Radiopharmaceuticals for diagnosing alzheimer's disease | SCHERING AG (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002036581-A1 | RADIOPHARMACEUTICALS FOR DIAGNOSING ALZHEIMER'S DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-10 | — | — | WO | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020131932-A1 | Radiopharmaceuticals for diagnosing alzheimer's disease | CCR1, CCR3, CCR2 | TAS1R3 855/4885TAS1R1 555/4885TAS1R2 1012/4885 |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | TAS1R3 4049/4885TAS1R1 4293/4885TAS1R2 3928/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | TAS1R3 3971/4885TAS1R1 3526/4885TAS1R2 3744/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | TAS1R3 4049/4885TAS1R1 4293/4885TAS1R2 3928/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | TAS1R3 4812/4885TAS1R1 4756/4885TAS1R2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.